Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: Putting the risk of resistance into perspective

Clinical Infectious Diseases

Volumn 48, Issue 10, 2009, Pages 1361-1363

  Low, Donald E ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATE; COHORT ANALYSIS; COMMUNITY; COMMUNITY ACQUIRED PNEUMONIA; DRUG USE; HUMAN; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NOTE; OUTPATIENT; POPULATION; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; RISK; COMMUNICABLE DISEASE; DRUG EFFECT; MICROBIOLOGY; PNEUMONIA;

COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PNEUMONIA; TUBERCULOSIS, PULMONARY;

EID: 65549137447     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598197     Document Type: Note

References (27)

1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72.
2. Davies TA, Yee YC, Goldschmidt R, et al. Decline in the prevalence of pandemic clones Spain23F-1 and Spain9V-3 among US fluo- roquinolone-resistant Streptococcus pneumoniae TRUST Surveillance isolates since 2001. Postgrad Med 2008;120:39-45.
3. Low DE. Fluoroquinolone-resistant pneu- mococci: maybe resistance isn't futile? Clin Infect Dis 2005;40:236-8.
4. Song JH, Ko KS, Lee MY, et al. In vitro activities of ertapenem against drug-resistant Streptococcus pneumoniae and other respiratory pathogens from 12 Asian countries. Diagn Microbiol Infect Dis 2006;56:445-50.
5. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management ofadult lower respiratory tract infections. Eur Respir J 2005;26:1138-80.
6. Spigelman MK. New tuberculosis therapeutics: a growing pipeline. J Infect Dis 2007;196(Suppl 1):S28-34.
7. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62.
8. Song JH, Oh WS, Kang CI, et al. Epidemiology and clinical outcomes ofcommunity-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 2008;31:107-14.
9. Yoon YS, Lee HJ, Yoon HI, et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 2005;9:1215-9.
10. Wang JY, Hsueh PR, Jan IS, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006;61:903-8.
11. Dooley KE, Golub J, Goes FS, et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002;34:1607-12.
12. Ginsburg AS, Woolwine SC, Hooper N, et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 2003;349:1977-8.
13. Long R, Chong H, Hoeppner V, et al. Empirical treatment of community-acquired pneumonia and the development of fluo- roquinolone-resistant tuberculosis. Clin Infect Dis 2009;48:1354-60 (in this issue).
14. Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003;37:1448- 52.
15. Ginsburg AS, Grosset JH, Bishai WR. Flu- oroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003;3:432-42.
16. Huang TS, Kunin CM, Shin-Jung LS, et al. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005;56:1058-62.
17. Wang JY, Lee LN, Lai HC, et al. Fluoroquin- olone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Anti- microb Chemother 2007;59:860-5.
18. Gaba PD, Haley C, Griffin MR, et al. Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med 2007;167:2317-22.
19. Escribano I, Rodriguez JC, Llorca B, et al. Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to flu- oroquinolones and linezolid. Chemotherapy 2007;53:397-401.
20. Iseman MD. Evolution of drug-resistant tuberculosis: a tale of two species. Proc Natl Acad Sci U S A 1994;91:2428-9.
21. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis 2007;44:681-8.
22. Almeida D, Nuermberger E, Tyagi S, et al. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a mu- rine model of tuberculosis. Antimicrob Agents Chemother 2007;51:4261-6.
23. Levofloxacin. Tuberculosis 2008;88:119-21.
24. Moxifloxacin. Tuberculosis 2008;88:127-31.
25. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of lev- ofloxacin, gatifloxacin and moxifloxacin in pulmonarytuberculosis. IntJTubercLungDis 2006;10:605-12.
26. Ji B, Lounis N, Maslo C, et al. In vitro and in vivo activities of moxifloxacin and clinaflox- acin against Mycobacterium tuberculosis. An- timicrob Agents Chemother 1998;42:2066-9.
27. Hsueh PR. Should fluoroquinolones be first- line antibiotics in the treatment of community-acquired pneumonia in areas with high incidence of tuberculosis? J Microbiol Immunol Infect 2007;40:386-7.